In line with this finding, rosiglitazone treatment prevented the development of NASH in a model of MCD-treated mice [55], and similar results were obtained using the PPARγ agonist pioglitazone [52, 53]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.